Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocrystalline megestrol acetate for appetite loss and nutritional risk in older adults
ChiCTR2600131626Phase 4Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in anorexia nervosa (AN) and Malnutrition comparing Placebo group with Nanocrystalline megestrol acetate group (2 arms). Primary endpoints: Improvements in appetite and body weight and Proportion of individuals with weight gain of at least 5% from baseline. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
megestrol
03
Conditions
anorexia nervosa (AN)Malnutrition
Beyond the preview
Go deeper on ChiCTR2600131626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131626.